Castleark Management LLC bought a new position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) during the second quarter, HoldingsChannel.com reports. The firm bought 301,845 shares of the specialty pharmaceutical company’s stock, valued at approximately $18,065,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SevenBridge Financial Group LLC purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $113,000. Cubist Systematic Strategies LLC purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $203,000. NumerixS Investment Technologies Inc purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $204,000. Everence Capital Management Inc. purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $205,000. Finally, Cim LLC purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $207,000. Institutional investors own 97.42% of the company’s stock.

In other news, VP Padmanabh P. Bhatt sold 7,205 shares of the firm’s stock in a transaction on Thursday, June 21st. The stock was sold at an average price of $60.00, for a total transaction of $432,300.00. Following the completion of the sale, the vice president now directly owns 14,705 shares of the company’s stock, valued at approximately $882,300. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Gregory S. Patrick sold 35,000 shares of the firm’s stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $56.63, for a total value of $1,982,050.00. Following the sale, the chief financial officer now directly owns 75,975 shares of the company’s stock, valued at $4,302,464.25. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,000 shares of company stock valued at $2,881,426. Insiders own 6.20% of the company’s stock.

A number of equities research analysts recently commented on the company. BidaskClub raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 22nd. Cantor Fitzgerald reissued a “buy” rating and issued a $56.00 price target on shares of Supernus Pharmaceuticals in a research report on Friday. ValuEngine lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 8th. Piper Jaffray Companies set a $47.00 price target on Supernus Pharmaceuticals and gave the company a “hold” rating in a research report on Monday, July 2nd. Finally, Stifel Nicolaus increased their price target on Supernus Pharmaceuticals from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, May 25th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. Supernus Pharmaceuticals has an average rating of “Buy” and an average target price of $54.09.

Shares of Supernus Pharmaceuticals stock opened at $48.05 on Monday. Supernus Pharmaceuticals Inc has a 1 year low of $33.30 and a 1 year high of $61.25. The firm has a market cap of $2.57 billion, a PE ratio of 38.13 and a beta of 0.83. The company has a quick ratio of 2.54, a current ratio of 2.74 and a debt-to-equity ratio of 0.82.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.14. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. The firm had revenue of $99.54 million during the quarter, compared to analyst estimates of $101.01 million. equities analysts expect that Supernus Pharmaceuticals Inc will post 1.98 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Further Reading: Leveraged Buyout (LBO) Explained

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.